10.98
0.29 (2.71%)
| Previous Close | 10.69 |
| Open | 10.70 |
| Volume | 2,138,443 |
| Avg. Volume (3M) | 5,022,901 |
| Market Cap | 1,789,020,544 |
| Price / Earnings (TTM) | 4.26 |
| Price / Sales | 1.65 |
| Price / Book | 33.20 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | 38.14% |
| Operating Margin (TTM) | 77.40% |
| Diluted EPS (TTM) | 2.75 |
| Quarterly Revenue Growth (YOY) | 610.30% |
| Quarterly Earnings Growth (YOY) | 179.90% |
| Current Ratio (MRQ) | 2.06 |
| Operating Cash Flow (TTM) | -189.21 M |
| Levered Free Cash Flow (TTM) | 61.88 M |
| Return on Assets (TTM) | 19.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Novavax, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -5.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.10 |
|
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 8.78% |
| % Held by Institutions | 57.19% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Shah Capital Management | 31 Dec 2025 | 14,558,780 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 19.00 (BTIG, 73.04%) | Buy |
| Median | 17.50 (59.38%) | |
| Low | 16.00 (HC Wainwright & Co., 45.72%) | Buy |
| Average | 17.50 (59.38%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 9.17 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Feb 2026 | 16.00 (45.72%) | Buy | 10.14 |
| BTIG | 20 Jan 2026 | 19.00 (73.04%) | Buy | 8.20 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CASEY MARK J | - | 9.82 | -12,592 | -120,287 |
| DRAGHIA-AKLI RUXANDRA | - | 9.49 | -11,313 | -107,360 |
| JACOBS JOHN C | - | 9.82 | -107,738 | -1,047,426 |
| KELLY JAMES PATRICK | - | 9.87 | -55,120 | -544,420 |
| O'HARA ELAINE | - | 9.82 | -38,773 | -378,579 |
| Aggregate Net Quantity | -225,536 | |||
| Aggregate Net Value ($) | -2,198,073 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 9.80 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KELLY JAMES PATRICK | Officer | 07 Mar 2026 | Disposed (-) | 5,904 | 9.98 | 58,922 |
| KELLY JAMES PATRICK | Officer | 07 Mar 2026 | Option execute | 12,223 | - | - |
| DRAGHIA-AKLI RUXANDRA | Officer | 03 Mar 2026 | Disposed (-) | 11,313 | 9.49 | 107,360 |
| DRAGHIA-AKLI RUXANDRA | Officer | 03 Mar 2026 | Option execute | 26,667 | - | - |
| CASEY MARK J | Officer | 03 Mar 2026 | Disposed (-) | 11,378 | 9.49 | 107,977 |
| CASEY MARK J | Officer | 03 Mar 2026 | Option execute | 37,500 | - | - |
| O'HARA ELAINE | Officer | 03 Mar 2026 | Disposed (-) | 22,429 | 9.49 | 212,851 |
| O'HARA ELAINE | Officer | 03 Mar 2026 | Option execute | 56,334 | - | - |
| KELLY JAMES PATRICK | Officer | 03 Mar 2026 | Disposed (-) | 20,850 | 9.49 | 197,867 |
| KELLY JAMES PATRICK | Officer | 03 Mar 2026 | Option execute | 43,167 | - | - |
| JACOBS JOHN C | Officer | 03 Mar 2026 | Disposed (-) | 69,288 | 9.49 | 657,543 |
| JACOBS JOHN C | Officer | 03 Mar 2026 | Option execute | 150,167 | - | - |
| CASEY MARK J | Officer | 01 Mar 2026 | Disposed (-) | 1,214 | 10.14 | 12,310 |
| CASEY MARK J | Officer | 01 Mar 2026 | Option execute | 4,000 | - | - |
| O'HARA ELAINE | Officer | 01 Mar 2026 | Disposed (-) | 16,344 | 10.14 | 165,728 |
| O'HARA ELAINE | Officer | 01 Mar 2026 | Option execute | 59,600 | - | - |
| KELLY JAMES PATRICK | Officer | 01 Mar 2026 | Disposed (-) | 28,366 | 10.14 | 287,631 |
| KELLY JAMES PATRICK | Officer | 01 Mar 2026 | Option execute | 58,666 | - | - |
| JACOBS JOHN C | Officer | 01 Mar 2026 | Disposed (-) | 38,450 | 10.14 | 389,883 |
| JACOBS JOHN C | Officer | 01 Mar 2026 | Option execute | 83,333 | - | - |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 20 Jan 2026 | Announcement | Novavax Announces Entering into a License Agreement with Pfizer |
| 07 Jan 2026 | Announcement | Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |